First Stage Investor

New Pick: Invest in Saving Millions of Lives

New Pick: Invest in Saving Millions of Lives
By Andy Gordon
Date August 31, 2020

Startup: Biopact CT
Security type: Common stock 
Valuation: $30 million 
Share price: $1.55 
Minimum investment: $465 
Where to invest: Equifund 
Deadline: February 12, 2021

Biopact CT ranks as one of the most extraordinary investment opportunities I’ve come across in a long time. In terms of upside — the ability of early investors to realize enormous gains — it shares the same rarified status as Phoenix Pharmaceuticals. 

I made that recommendation in December 2018. If you recall, Phoenix Pharma developed a non-addictive opioid pain killer. If it gets it right, there’s no question it will garner global massive sales. 

The difference between Phoenix and Biopact is on the technology side. Phoenix Pharma still needs to prove its tech to the FDA. It’s going to take years. 

Biopact’s tech doesn’t require FDA approval. It’s ready to roll out now. 

And Biopact’s technology — though new — has passed every test so far. It works exactly how it’s supposed to. 

And that’s great news for the millions of patients suffering from debilitating diseases like diabetes, osteoporosis and dozens of cancers. 

No, Biopact hasn’t discovered the cure for all these incurable diseases. But it does the next best thing. It delivers proven and effective payloads to fight these diseases. 

And that’s key. 

Because our war on cancer (and other diseases) is not unlike any other war. To win you need to build and amass weapons. But weapons are useless if you can’t deliver or guide them to where they are needed

The same is true in the medical field. In fact, it’s why…

  • The CAR-T therapy for cancer costs $425,000. (CAR-T involves genetically altering a patient’s own T-cells — a type of immune system cell — so they can seek out and attack specific cancer cells.)
  • Cell therapy for a form of inherited vision loss costs $475,000
  • Cell therapy treatment for spinal muscular atrophy costs $2.1 million.

These cell engineering therapies are incredibly powerful tools. They can destroy tumors, repair tissues and reduce, stop and reverse the spread of malignant cells. And they work! They have a success rate of around 60% to 70%.  

That’s beyond remarkable. It should represent a giant leap for patients. These therapies should be available to every patient who suffers from one of these diseases. They should be saving hundreds if not thousands of lives. At the very least, they should be preventing untold suffering.

But they don’t. Because all of these therapies are too expensive.

Medicare simply can’t afford to cover the astronomical prices of these therapies. Insurance companies cover some — but not enough for most patients. That begs the question — why is it so expensive?

The treatments themselves cost a lot. They were expensive to develop. And pharmaceutical companies charge a lot to recoup those expenses and make a little profit. But that’s only half the story.

The other half is that cell therapy requires genetic editing — that is, changing the makeup and gene function of the cell — to effectively fight disease. 

Genetic editing has to be done inside the cell. But the medical industry doesn’t have a good way of introducing genetic material into cells. Right now, they do it through viruses. 

Which causes a lot of problems. Viruses are damaging and hard to control. They destroy millions of the cells they target. Many of the cells that survive have damaged cell membranes, rendering them useless. Lab technicians have to use a lot of genetic material because so much of it ends up not being used. 

It’s inefficient, wasteful, expensive and time-consuming. 

And the industry has no idea how to solve this mess. Truth is, doctors and technicians use viruses because there is no other practical alternative. They’re so bereft of options that they’ve been reduced to trying to develop less toxic viruses

Biopact solves this problem.

In fact, it is the only company in the world right now that has a true solution. It has developed the only effective and proven intracellular delivery vehicle. It works. It’s being used right now. And its payload or cargo will be able to treat dozens of diseases. 

The delivery vehicle is tiny — hollow nanotubes half the width of a coronavirus. They’re non-carcinogenic, inert and can carry all kinds of protein. And cells let them right in through a process is called endocytosis.

This technology is very safe (with a nearly 100% cell survival rate) and much more efficient than using viruses. And it saves hundreds of thousands of dollars per treatment. It can deliver all kinds of payloads… from gene-editing CRISPR molecules to cancer-fighting CAR-T treatments — as well as all kinds of drugs, proteins and other medicines. 

It’s exactly what patients need. And nobody else has it. To keep it that way, Biopact has built a wall of 77 patents to protect its remarkable technology from copycats. 

The core technology was developed by the inventor of Crocs and the ubiquitous zip bag — Kurt Swogger. While working as the VP of Research & Development at Dow Chemical, he was directly responsible for creating products that delivered more than $30 billion worth of value to Dow. 

And now he wants to do something similar for Biopact. If I heard that from anybody else, I’d say that person was over-reaching. But from Kurt — master inventor, 35-year veteran in the high-tech materials industry, savvy businessman and proven generator of wealth — I say go for it. 

In fact, as the only company providing a solution that moves the industry away from its dependence on toxic viruses, Kurt sees this as a massive opportunity to address a market worth hundreds of billions of dollars. 

It’s the same way I see it too. And I don’t say that lightly. You see, when something is too good to be true, well, it usually is. And when I first saw this massively outsized opportunity, it seemed too amazing. So I probed. I argued. I told Kurt that treatment even with his delivery system treatment was too expensive. He disagreed and told me that saving hundreds of thousands of dollars per treatment brings it into the realm of coverage by Medicare and other reputable insurance companies. 

“If you cut the costs in half, the market opens up,” he said. But it’s too different, I said. The medical community hates that. He agreed. His technology won’t be an overnight sensation. It’ll take some time to be widely adopted. 

But for most game-changing technologies, he said, it takes longer. “A couple of years is perfectly reasonable.” 

He told me that he has the attention of both big and small pharmaceuticals. He argued that the market risk is insignificant. “As companies see the technology work, the benefits of adopting it will be too powerful to resist.” And at this point, he added, the technological risk is negligible. “There’s no doubt in my mind it works.”

And that’s what makes Biopact such a unique investment opportunity. The risk has been reduced to almost next to nothing. And the reward is off the charts. Let’s start with unicorn status ($1 billion valuation) and go up from there. 

The question isn’t why should you invest? Really, it’s how on earth can you not? 

How to Invest

Biopact is raising up to $1.07 million on Equifund. If you don’t already have an Equifund account, you’ll need to sign up for one. Once you verify your account and are logged in to Equifund, visit the Biopact deal page. Then click the orange button that says “Invest Now.” Enter the amount you want to invest, starting as low as $465, and proceed through the required steps. Be sure your investment is confirmed, then you’re good to go.


This opportunity, like all early-stage investments, is risky. Early-stage investments often fail. The investment you’re making is NOT liquid. Expect to hold your position for five to 10 years. An earlier exit is always possible but should not be expected.

All that said, I believe Biopact offers a very attractive risk-reward ratio.

Top Posts on Early Investing